Bibliografia UJ CM

1/3
Philipp Bernhard Staber, Wojciech Jurczak, Richard Greil, Vladan Vucinic, Jan Moritz Middeke, Marco Montillo, Talha Munir, Peter Neumeister, Johannes Schetelig, Stephan Stilgenbauer, Frank Striebel, Maren Dirnberger-Hertweck, Johannes Weirather, Wolfram Brugger, Peter Kelemen, Clemens-Martin Wendtner, Jennifer Ann Woyach.
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor.
Leukemia & Lymphoma
2021 : Vol. 62, nr 14, s. 3440-3451, il., bibliogr. 32 poz., abstr.
Autor korespondencyjny: Philipp Bernhard Staber.
Both authors contributed equally as first authors: Philipp Bernhard Staber and Wojciech Jurczak.
p-ISSN: 1042-8194
e-ISSN: 1029-2403
AZ
ORG
AIF
IF: 2.996
Adres url:
Streszczenie w PubMed:
2/3
Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Peter Hillmen, John F. Seymour, Steven Coutre, Wojciech Jurczak, Stephen P. Mulligan, Anna Schuh, Sarit Assouline, Clemens-Martin Wendtner, Andrew W. Roberts, Matthew S. Davids, Johannes Bloehdorn, Talha Munir, Sebastian Bottcher, Lang Zhou, Ahmed Hamed Salem, Monali Desai, Brenda Chyla, Jennifer Arzt, Su Young Kim, Maria Verdugo, Gary Gordon, Michael Hallek, William G. Wierda.
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial .
Journal of Clinical Oncology
2018 : Vol. 36, nr 9, s. 1973-1980
Autor korespondencyjny: Stephan Stilgenbauer.
p-ISSN: 0732-183X
AZ
ORG
AIF
IF: 28.245
Adres url:
Streszczenie w PubMed:
DOI:
3/3
Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Steven Coutre, John F. Seymour, Talha Munir, Soham D. Puvvada, Clemens-Martin Wendtner, Andrew W. Roberts, Wojciech Jurczak, Stephen P. Mulligan, Sebastian Böttcher, Mehrdad Mobasher, Ming Zhu, Monali Desai, Brenda Chyla, Maria Verdugo, Sari Heitner Enschede, Elisa Cerri, Rod Humerickhouse, Gary Gordon, Michael Hallek, William G. Wierda.
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Lancet. Oncology
2016 : Vol. 17, nr 6, s. 768-778, il., bibliogr. 30 poz., sum.
p-ISSN: 1470-2045
AZ
ORG
AIF
IF: 33.900
Adres url:
Streszczenie w PubMed:
Wyświetl ponownie stosując format:

Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie | Biblioteka Medyczna UJ